Medicine has long drawn a single line through the KRAS gene, treating all mutations as one verdict: resistant. A study published in Nature now asks whether that line was drawn too broadly, finding that colorectal cancers carrying the G13 variant of KRAS respond to anti-EGFR antibody therapy much as unmutated tumors do — while G12-mutant tumors remain resistant. In the slow work of precision oncology, this distinction is not merely academic; it is the kind of refinement that determines which patients are offered a chance at treatment and which are quietly turned away.
KRAS G13 mutations retain anti-EGFR sensitivity in colorectal cancer, unlike G12 variants
Not all KRAS mutations are created equal.
Mark
Why does it matter that G13 and G12 are different? Aren't they both just KRAS mutations?
Mimi
They're both mutations in the same gene, but they seem to wire the cell differently. G12 shuts down the EGFR pathway's ability to kill the cancer cell. G13 doesn't—or at least not completely. The cell still responds to the drug.
Mark
So you're saying doctors have been denying a drug to some patients who might actually benefit from it?
Mimi
Exactly. Right now, if your tumor has any KRAS mutation, you're excluded from anti-EGFR therapy. But if you have G13, you might respond. The current rule treats all KRAS mutations the same, and that's too broad.
Mark
What's actually happening inside the G13 cells when the drug works?
Mimi
The drug is triggering a different death pathway. In G13 cells, MYC signaling gets activated, and that seems to make the cells more vulnerable to apoptosis—programmed cell death. It's like the drug is finding a back door into the cell's survival machinery.
Mark
Could you use that knowledge to make the drug work better?
Mimi
That's the next question. If MYC activation is what makes G13 cells sensitive, maybe blocking MYC at the same time would make the drug even more effective. Or maybe you could use MYC status as another filter to identify which patients will respond.
Mark
How confident are you in this? Is this organoid data going to change how doctors treat patients?
Mimi
The organoid work is solid—it's patient-derived tissue, not just cell lines. But it needs validation in larger patient studies before it changes guidelines. What's clear is that the current one-size-fits-all approach to KRAS mutations is too crude.
El Pulso
- Thousands of colorectal cancer patients are currently denied anti-EGFR therapy based on a blanket rule that any KRAS mutation means the drugs won't work.
- Patient-derived tumor organoids exposed this rule's blind spot: G13-mutant tumors responded to anti-EGFR antibodies nearly as well as unmutated tumors, while G12-mutants held firm in their resistance.
- Researchers traced the mechanism to MYC signaling — a pathway governing cell growth — which appears activated in G13-mutant tumors upon treatment, helping tip cells toward programmed death.
- Blocking MYC signaling experimentally reduced that drug sensitivity, confirming the pathway's role and hinting at possible combination therapies.
- The findings are now pressing against clinical guidelines, raising the prospect that G13-mutant patients could be reclassified as eligible for treatments currently withheld from them.
Medicine has long drawn a single line through the KRAS gene, treating all mutations as one verdict: resistant. A study published in Nature now asks whether that line was drawn too broadly, finding that colorectal cancers carrying the G13 variant of KRAS respond to anti-EGFR antibody therapy much as unmutated tumors do — while G12-mutant tumors remain resistant. In the slow work of precision oncology, this distinction is not merely academic; it is the kind of refinement that determines which patients are offered a chance at treatment and which are quietly turned away.
For years, oncologists have followed a firm rule: a KRAS mutation in a colorectal tumor means anti-EGFR antibodies won't work. The logic was clean, the guideline clear. But a new study built on patient-derived tumor organoids suggests that rule has been flattening a more complicated truth.
Researchers tested eight organoid lines — drawn directly from patient tumors — representing wild-type KRAS, the G12 variant, and the G13 variant. When exposed to anti-EGFR antibodies, the G12-mutant organoids behaved exactly as expected, resisting the drugs. The G13-mutant organoids did not. They responded nearly as well as the unmutated tumors, a result that cuts against the binary logic that has governed KRAS-based treatment decisions for decades.
To understand why, the team examined gene expression in G13-mutant organoids after treatment. Two signals stood out: enriched activity in MYC signaling — a pathway tied to cell growth and survival — and increased expression of genes associated with programmed cell death. When they pharmacologically suppressed MYC signaling, the organoids' sensitivity to anti-EGFR therapy partially faded, suggesting MYC activation is genuinely part of how these tumors become vulnerable to the drug.
The clinical stakes are real. Current treatment algorithms exclude all KRAS-mutant patients from anti-EGFR therapy without distinction. If these findings extend to larger patient cohorts, that exclusion may need to be redrawn. Patients with G13-mutant tumors — currently turned away — could become eligible for a therapy that, by the new data, may actually work for them. The research also points toward combination strategies: pairing anti-EGFR antibodies with MYC inhibitors, or using MYC activity as an additional marker for patient selection.
Precision medicine advances this way — not in sweeping revisions, but in the careful disaggregation of what once seemed uniform. The KRAS gene remains one of cancer biology's most consequential targets, but the lesson here is that asking whether a mutation is present may no longer be enough. The question that matters is which mutation — and what it does to the cell when a drug arrives.
For years, oncologists have used a simple rule: if a colorectal cancer patient's tumor carries a KRAS mutation, don't bother with anti-EGFR antibodies. The drugs won't work. It's been standard practice, embedded in treatment guidelines, shaping decisions for thousands of patients. But a new study using patient-derived tumor organoids suggests that rule needs refinement—and that some patients currently written off as untreatable might actually benefit from the therapy.
The distinction comes down to precision. Not all KRAS mutations are created equal. Researchers tested eight organoid lines derived directly from patient tumors: some with wild-type KRAS (unmutated), some carrying the G12 variant, and some with the G13 variant. When they exposed these organoids to anti-EGFR antibodies, a clear pattern emerged. The G12-mutant organoids behaved as expected—they resisted the drugs, showing the reduced responsiveness that has long defined KRAS-mutant colorectal cancer. But the G13-mutant organoids did something unexpected. They responded to anti-EGFR treatment nearly as well as the wild-type tumors did.
This finding challenges a foundational assumption in precision oncology. For decades, KRAS mutation status has functioned as a binary switch: mutated equals resistant. The new data suggest the reality is more granular. The G13 variant appears to occupy a different therapeutic space than its G12 cousin, despite both being mutations in the same gene. To understand why, the researchers dug into the molecular machinery. When they analyzed gene expression in G13-mutant organoids after anti-EGFR treatment, they found significant shifts in how cells were behaving. Notably, genes tied to MYC signaling—a pathway that drives cell growth and survival—showed enriched activity. At the same time, genes associated with programmed cell death lit up, suggesting the drug was triggering apoptosis through a distinct mechanism.
They tested this hypothesis further. Using publicly available cancer cell line datasets, they confirmed that G13-mutant cells generally showed lower IC50 values (meaning they needed less drug to achieve the same effect) compared to G12-mutant cells. When they pharmacologically blocked MYC signaling in their organoids, the sensitivity to anti-EGFR antibodies partially diminished, indicating that MYC activation was genuinely contributing to the therapeutic response. The picture that emerged was one of subtype-specific vulnerability—different mutations in the same gene triggering different downstream consequences, which in turn determine whether a drug can work.
The implications ripple outward into clinical practice. Current treatment algorithms exclude all KRAS-mutant patients from anti-EGFR therapy. If these findings hold in larger patient cohorts, that blanket exclusion could change. Patients with G13-mutant tumors might be candidates for drugs they're currently denied. The work also opens a window into mechanism: understanding that MYC signaling mediates response in G13-mutant tumors suggests potential combination strategies—pairing anti-EGFR antibodies with MYC inhibitors, for instance, or using MYC status as an additional stratification marker.
This is how precision medicine advances, one mutation at a time. The KRAS gene has long been a focal point of cancer research precisely because it's so frequently altered and so consequential. But treating all KRAS mutations identically has always been a blunt instrument. The organoid data suggest that the next generation of treatment decisions will need to be more specific—not just asking whether a tumor has a KRAS mutation, but which one, and what that particular variant does to the cell's response to therapy. For patients with G13-mutant colorectal cancers currently excluded from anti-EGFR treatment, that distinction could be the difference between a drug that works and one that doesn't.
Citas Notables
KRAS G13-mutant organoids demonstrated sensitivity comparable to that of KRAS wild-type organoids, while G12-mutant organoids generally exhibited reduced responsiveness to anti-EGFR antibodies.— Study findings
Quieres la nota completa?
Lee el original en Nature ↗
Health & Medicine